SAN DIEGO--(BUSINESS WIRE)--April 11, 2006--Illumina, Inc. (NASDAQ:ILMN - News) announced today that it has signed a genotyping services agreement to support prostate cancer researchers funded by Cancer Research UK, the world’s leading independent charity dedicated to cancer research. Under the terms of the agreement, valued at nearly $7 million, Illumina’s service group will conduct whole-genome genotyping (greater than 550,000 single nucleotide polymorphisms, or SNPs, per sample) for at least 4,000 well-classified prostate patients and controls. A second phase will involve development of a custom, 12-sample BeadChip that will enable analysis of 24,000 SNPs per sample and be used to genotype at least 8,000 samples. Both phases will use Illumina’s Sentrix® BeadChips and Infinium(TM) Assay with the option to employ related assay methods.
